Neonc Technologies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding, Subsidiary
- Established
- 2008-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.neonctech.com
Clinical Trials
4
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)A Study of the Safety, Dosing, and Delivery of NEO100 in Patients with Pediatric Brain Tumors
Phase 1
Not yet recruiting
- Conditions
- Diffuse Midline Glioma, H3 K27M-MutantPediatric Tumor of Brain StemPineocytomaSpinal Cord TumorPediatric Tumor of BrainHigh Grade GliomaPediatric Tumor of CNSChoroid Plexus Carcinoma, Childhood
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Neonc Technologies, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06357377
Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1
Recruiting
- Conditions
- Glioblastoma, IDH-wildtypeHead and Neck Squamous Cell CarcinomaMelanomaMerkel Cell CarcinomaMismatch Repair Deficient Solid Malignant TumorMicrosatellite Instability-High Colorectal CancerColorectal CancerMicrosatellite Instability-High Solid Malignant TumorNon-small Cell Lung CancerRenal Cell Carcinoma
- Interventions
- Drug: NEO212 Oral CapsuleDrug: FOLFIRI Protocol
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Neonc Technologies, Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT06047379
- Locations
- 🇺🇸
Precision NextGen Oncology, Beverly Hills, California, United States
🇺🇸Northwest Medical Specialties, Tacoma, Washington, United States
NEO100 and High-Grade Meningioma
Phase 2
Recruiting
- Conditions
- Residual, Progressive or Recurrent Grade II or III Meningioma
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Neonc Technologies, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05023018
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Neonc Technologies, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT02704858
- Locations
- 🇺🇸
Atlantic Health (Overlook Medical Center), Summit, New Jersey, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Georgia Cancer Center (Augusta University), Augusta, Georgia, United States
News
No news found